Home › Funds › ABRAMS CAPITAL MANAGEMENT, L.P. › NUVB

ABRAMS CAPITAL MANAGEMENT, L.P. position in NUVB

NUVATION BIO INC · Health Care

ABRAMS CAPITAL MANAGEMENT, L.P. reported holding 1,270,504 shares of NUVB (NUVATION BIO INC) in its Q3 2026 13F filing — a position valued at US$7.1M, representing 0.15% of its reported portfolio and ranking #11 among its reported holdings. ABRAMS CAPITAL MANAGEMENT, L.P. has disclosed NUVB holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)1.27M sh
Reported value held$7.11M
Portfolio Weight0.15%
First reportedQ3 2023
Last changeHold
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How ABRAMS CAPITAL MANAGEMENT, L.P.'s NUVB position evolved

ABRAMS CAPITAL MANAGEMENT, L.P. first disclosed a stake in NUVB in Q3 2023 at 3,811,513 shares (US$5.1M). The position peaked in Q4 2025 at 3,811,513 shares, worth US$34.2M. Across 13 filings, ABRAMS CAPITAL MANAGEMENT, L.P. increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 11 time(s). The most recent filing (Q3 2026) shows 1,270,504 shares valued at US$7.1M. Notable position changes include a 67% trim in Q1 2026 (shares rose 32% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 3.81M $5.11M New
Q4 2023 3.81M $5.76M Hold
Q1 2024 3.81M $13.87M Hold
Q2 2024 3.81M $11.13M Hold
Q3 2024 3.81M $8.73M Hold
Q4 2024 3.81M $10.14M Hold
Q1 2025 3.81M $6.71M Hold
Q2 2025 3.81M $7.43M Hold
Q3 2025 3.81M $14.10M Hold
Q4 2025 3.81M $34.15M Hold
Q1 2026 1.27M $5.45M Reduce
Q2 2026 1.27M $7.22M Hold
Q3 2026 1.27M $7.11M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NUVB and 13F data

NUVB (NUVATION BIO INC) is a Health Care company. 54 other funds we track also report a position in NUVB — the largest reported positions include Decheng Capital LLC (US$145.3M), Context Capital Management, LLC (US$53.1M), Omega Fund Management, LLC (US$45.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NUVB

All NUVB fund holders →

FAQ

How long has ABRAMS CAPITAL MANAGEMENT, L.P. held NUVB?

ABRAMS CAPITAL MANAGEMENT, L.P. has disclosed NUVB holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is ABRAMS CAPITAL MANAGEMENT, L.P.'s current position in NUVB?

As of Q3 2026, ABRAMS CAPITAL MANAGEMENT, L.P. holds 1.27M shares of NUVB (NUVATION BIO INC), valued at $7.11M, representing 0.15% of its reported portfolio and ranking #11.

Has ABRAMS CAPITAL MANAGEMENT, L.P. been buying or selling NUVB?

In the latest 13F filing (Q3 2026), ABRAMS CAPITAL MANAGEMENT, L.P. held unchanged its position in NUVB. The position peaked in Q4 2025 at 3.81M shares.

Which other funds hold NUVB?

Other major institutional holders of NUVB include Decheng Capital LLC, Context Capital Management, LLC, Omega Fund Management, LLC, among 54 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.